Core Insights - Value investors traditionally use the price-to-earnings (P/E) ratio to identify value stocks, but for loss-making companies, the price-to-sales (P/S) ratio is more relevant. The price-to-book (P/B) ratio is also a useful tool for identifying undervalued stocks with high return potential [1][5][9]. Valuation Ratios - The P/B ratio is calculated as market capitalization divided by book value of equity, helping to identify low-priced stocks with high growth prospects [2][5]. - A P/B ratio of less than one indicates that a stock is trading below its book value, suggesting it may be undervalued, while a ratio above one may indicate overvaluation [5][6]. - The P/B ratio is particularly useful for industries with tangible assets, such as finance and manufacturing, but can be misleading for companies with high R&D expenses or significant debt [8]. Book Value Definition - Book value represents the total value remaining for shareholders if a company were to liquidate its assets after settling all liabilities, calculated by subtracting total liabilities from total assets [3][4]. Screening Parameters - Stocks with a P/B ratio lower than the industry median are considered to have potential for price appreciation [11]. - Additional screening criteria include a P/S ratio below the industry median, a P/E ratio below the industry median, a PEG ratio less than 1, a current price of at least $5, an average 20-day volume of at least 100,000, and a Zacks Rank of 1 or 2 [12][13][14]. Selected Stocks - Five stocks identified with low P/B ratios and solid growth potential include: - **StoneCo (STNE)**: Financial technology solutions provider with a projected 3-5 year EPS growth rate of 30.3% and a Zacks Rank of 2 [15]. - **Great Lakes Dredge & Dock (GLDD)**: Largest U.S. dredging services provider with a projected EPS growth rate of 12.0% and a Zacks Rank of 1 [16]. - **EnerSys (ENS)**: Manufacturer of industrial batteries with a projected EPS growth rate of 15.0% and a Zacks Rank of 2 [17]. - **MillerKnoll (MLKN)**: Design solutions provider with a projected EPS growth rate of 12.0% and a Zacks Rank of 2 [17]. - **Keros Therapeutics (KROS)**: Clinical-stage biotech with a projected EPS growth rate of 23.6% and a Zacks Rank of 1 [18].

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment Group 1: Company Performance - Wayfair (W) has seen a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Tesco (TSCDY) has experienced a 4.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - MillerKnoll (MLKN) has reported a 3.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Grocery Outlet (GO) has seen a 1.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - ABB (ABBNY) has experienced a 1.2% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4]

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment Group 1: Company Performance - Guess (GES) has seen a Zacks Consensus Estimate for its current year earnings increase of 8.1% over the last 60 days [1] - Argan (AGX) has experienced a Zacks Consensus Estimate for its current year earnings increase of 6.5% over the last 60 days [2] - Elbit Systems (ESLT) has had a Zacks Consensus Estimate for its current year earnings increase of 4.2% over the last 60 days [3] - MillerKnoll (MLKN) has seen a Zacks Consensus Estimate for its current year earnings increase of 3.3% over the last 60 days [3] - UBS (UBS) has experienced a Zacks Consensus Estimate for its current year earnings increase of 2.2% over the last 60 days [4]